Literature DB >> 12872050

Influence of left ventricular mass, uremia and hypertension on vagal tachycardic reserve.

Luca Mircoli1, Rodolfo Rivera, Giuseppe Bonforte, Luigi Fedele, Simonetta Genovesi, Maurizio Surian, Alberto U Ferrari.   

Abstract

BACKGROUND: Left ventricular (LV) hypertrophy, arterial hypertension and end-stage renal disease (ESRD) are associated with deranged cardiac parasympathetic regulation and increased cardiovascular risk. These conditions often co-exist but little is known about the relative contribution of LV mass, arterial blood pressure and ESRD to impaired cardiac vagal tone. We evaluated the vagal tachycardic reserve (VTR) in subjects with normal renal function (age 58.4 +/- 6.6 years, n = 19) and in patients under chronic hemodialysis (HD) (age 62.6 +/- 13.2 years, n = 30) having wide ranges of LV mass and blood pressure.
METHODS: VTR was estimated from the tachycardic response to atropine (15 microg/kg intravenously) administered during a dipyridamole-atropine stress-echo test performed as part of the diagnostic work-up for identification of inducible myocardial ischemia. LV hypertrophy (defined as LV mass index > 125 g/m2 in both genders) was present in 20 HD patients and in nine control patients. Only patients free of inducible myocardial ischemia were included in the study.
RESULTS: The atropine-mediated tachycardia was: (i) significantly smaller in HD patients than in control patients (34.7 +/- 7.6 versus 60.8 +/- 10.5 beats/min, P < 0.01); (ii) independently and inversely related to LV mass (multiple regression; partial coefficients, -0.139 in HD patients and -0.382 in controls, both P < 0.01) and to mean blood pressure (-0.171 in HD patients and -0.268 in controls, both P < 0.01).
CONCLUSIONS: LV mass is the strongest (inverse) determinant of VTR. Blood pressure as well as the patient's renal status are also independent correlates of VTR, and the concomitance of LV hypertrophy and ESRD exacerbates the impairment of VTR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872050     DOI: 10.1097/00004872-200308000-00020

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 2.  Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 3.  Current Approaches to Quantifying Tonic and Reflex Autonomic Outflows Controlling Cardiovascular Function in Humans and Experimental Animals.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-11       Impact factor: 5.369

4.  Regression of left ventricular hypertrophy in diabetic nephropathy: loss of parasympathetic function predicts response to treatment.

Authors:  Larry A Weinrauch; Andrew J Berger; Doron Aronson; Ray E Gleason; Annette T Lee; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-05       Impact factor: 3.738

5.  Pulmonary hypertension and cardiac hypertrophy in children recipients of orthotopic living related liver transplantation.

Authors:  Magd A Kotb; Inas Abd El Satar; Ahmed M Badr; Nancy H Anis; Hoda Abd El Rahman Ismail; Alaa F Hamza; Hesham M Abdelkader
Journal:  J Adv Res       Date:  2017-07-27       Impact factor: 10.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.